Pulse Biosciences Inc PLSE.OQ reported a quarterly adjusted loss of 20 cents per share for the quarter ended June 30. The lone analyst forecast for the quarter was for a loss of 26 cents per share.
Reported revenue was zero; analysts expected zero.
Pulse Biosciences Inc's reported EPS for the quarter was a loss of 28 cents.
The company reported a quarterly loss of $19.17 million.
Pulse Biosciences Inc shares had fallen by 1.4% this quarter and lost 14.5% so far this year.
FORECAST CHANGES
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Pulse Biosciences Inc is $22.00, about 32.4% above its last closing price of $14.88
This summary was machine generated from LSEG data August 12 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2025 | -0.26 | -0.20 | Beat |